Integra LifeSciences Reports $14.9 Million Net Income in Q3 2026, Recovery from Previous Year

Integra LifeSciences Holdings Corporation reported a net income of $14.9 million, or $0.19 per diluted share, for the third quarter of 2026, a significant recovery from a net loss of $5.4 million, or $(0.07) per diluted share, in the same period last year. For the nine months ending September 30, 2026, the company achieved a net income of $14.7 million compared to a substantial loss of $514.8 million in the prior year. The improved financial performance is attributed to the absence of a goodwill impairment charge that had negatively impacted results in the previous year, alongside operational improvements.

Total revenue for the third quarter of 2026 reached $411.2 million, marking a 2.3% increase from $402.1 million in the same quarter of 2025. The Specialty Surgery segment, which includes neurosurgery and surgical instruments, generated $304.1 million, up 4% year-over-year, while the Tissue Reconstruction segment saw a slight decline to $107.1 million, down 2%. The revenue growth in Specialty Surgery was partially offset by a $7 million revenue loss due to operational disruptions from flooding at the Cincinnati facility.

In terms of operational metrics, Integra's total costs and expenses for the third quarter were $392.3 million, slightly higher than $390.3 million in the prior year. The company reported a gross margin of 51.0%, down from 51.5% in the previous year, reflecting increased costs associated with the Cincinnati flooding and other operational challenges. Research and development expenses decreased to $21.9 million from $22.5 million, while selling, general, and administrative expenses also saw a reduction, indicating cost-saving measures are taking effect.

Integra's balance sheet showed total assets of $3.5 billion as of September 30, 2026, down from $3.6 billion at the end of 2025. The company reported cash and cash equivalents of $252.3 million, an increase from $235.0 million at the end of the previous year. The company’s working capital improved to $860.9 million, driven by a reclassification of borrowings from current to long-term liabilities following an amendment to its Securitization Facility.

Looking ahead, Integra LifeSciences is focused on enhancing its operational capabilities and expanding its product offerings. The company has recently completed the acquisition of manufacturing assets from Greer Manufacturing, Inc. for $15 million, which will bolster its Neurosurgery segment. The company anticipates continued growth driven by new product launches and geographic expansion, despite ongoing challenges related to tariffs and regulatory compliance.